First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration
Authors:
- James S. TalksJTJames S. Talks
- Andrew J. LoteryALAndrew J. Lotery
- Martin McKibbinMMMartin McKibbin
- Aires LoboALAires Lobo
- Bobby PaulBPBobby Paul
- Qureshi KashifQKQureshi Kashif
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 123 (2) , 337-343
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBritish Journal of Ophthalmology, 2014
- The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab InjectionsOphthalmology, 2014
- Comparison of Outcomes from a Phase 3 Study of Age-Related Macular Degeneration with a Matched, Observational CohortOphthalmology, 2014
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular DegenerationOphthalmology, 2013
- Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2012
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006